The acquisition of Protein Metrics expands Insightful Science’s R&D solutions to include proteomics.
Insightful Science, as US-based software company, completed its acquisition of Protein Metrics, a US-based provider of biopharmaceutical protein characterization and proteomics analysis software, in December 2021. With this acquisition, Insightful Science expands its R&D offerings in the biopharmaceutical protein analysis arena, allowing the company to unblock data analysis bottlenecks currently associated with large-scale protein studies.
Biotherapeutic protein characterization and proteomics are critical for innovation in biomarker and biologic drug discovery, vaccines, and therapeutic products, Insightful Science stated in a Dec. 21, 2021, company press release. Protein Metrics provides a platform solution for protein analytical study from research through to industrial production that offers substantially more information than previous technologies. Previous technologies which require time consuming manual analysis by experts, according to the press release.
Protein Metrics’ software allows scientists to perform highly accurate analyses on data generated from all major commercially available liquid chromatography, capillary electrophoresis, and mass spectrometry platforms. The products’ algorithms are designed to help researchers minimize ambiguity, achieve reproducibility, and eliminate lab-to-lab variability, according to the press release.
Insightful Science will incorporate Protein Metrics’ technologies into its growing portfolio of scientific R&D software solutions, including GraphPad Prism, SnapGene, Geneious Prime, Dotmatics, and nQuery.
“We have been committed to understanding protein science and biopharma development since our inception, and our expertise in algorithm design and software engineering aligns entirely with Insightful Science’s dedication to advancing scientific discovery. Being part of Insightful Science will allow us to continue to offer a vendor-neutral platform for our customers and to continue to invest significantly in advancing our products. We look forward to working with our new colleagues to apply novel approaches to designing data platforms and thereby give customers greater insights into their research,” said Eric Carlson, president and CEO of Protein Metrics, in the press release.
“We are thrilled to welcome Protein Metrics into our company and help advance our vision to build the world’s largest scientific platform that can support customers through every step of the R&D process. The acquisition of Protein Metrics expands our value chain to include proteomics—a very fast-growing and innovative area of science. With world-class technology, strong financial performance, and a team that shares a focus on customer success, we are excited about our potential to add to our capabilities and further enhance scientific execution and collaboration,” said Thomas Swalla, CEO of Insightful Science, in the press release.
Source: Insightful Science
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.